1. Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort

   • Yuanyuan Pei
   • Jihong Zhu
   • Yin Su

   Original Article 24 January 2024 Pages: 695 - 703

   

2. A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)

   • Carlos Vallejo
   • Ana Rosell
   • M. Lorena Codesido

   Original Article 04 January 2024 Pages: 705 - 713

   

3. A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio

   • Cuicui Feng
   • Zhengjie Hua
   • Yini Wang

   Original Article Open access 10 January 2024 Pages: 715 - 723

   

4. Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut

   • Blanca Vegas Villalmanzo
   • Rodrigo Cantera Estefanía
   • Jorge Martínez Nieto

   Research 27 January 2024 Pages: 725 - 727

5. Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia

   • Pengli Huang
   • Henghui Chang
   • Huyong Zheng

   Original Article 28 December 2023 Pages: 729 - 736

   

6. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology

   • Marta Garrote
   • Mónica López-Guerra
   • Alberto Alvarez-Larrán

   Original Article Open access 24 January 2024 Pages: 737 - 747

   

7. Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival

   • Sohini Chattopadhyay
   • Sharon Lionel
   • Biju George

   Original Article 20 January 2024 Pages: 749 - 758

   

8. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study

   • Ludovic Gabellier
   • Pierre Peterlin
   • Emmanuel Raffoux

   Original Article Open access 26 January 2024 Pages: 759 - 769

   

9. Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis

   • Jialin Cui
   • Miaomiao Zhao
   • Qian Sun

   Original Article 31 January 2024 Pages: 771 - 780

   

10. CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia

    • Heba A. Ahmed
    • Asmaa Nafady
    • Ahmed Ahmed Allam

    Original Article Open access 09 November 2023 Pages: 781 - 792

    

11. Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study

    • Peng Sun
    • Hang Yang
    • Zhiming Li

    Original Article 13 November 2023 Pages: 793 - 801

    

12. Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study

    • Odil Giladi
    • Gianmarco Bagnato
    • Ronit Gurion

    Original Article 11 November 2023 Pages: 803 - 811

    

13. A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters

    • Ayşegül Aksu
    • Kadir Alper Küçüker
    • Bülent Turgut

    Original Article 15 November 2023 Pages: 813 - 822

    

14. Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin’s lymphoma: A single-center prospective study

    • So Okubo
    • Kohei Shinmura
    • Tomonori Nakazato

    Original Article 27 November 2023 Pages: 823 - 831

    

15. NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia

    • Chun-Yu Shang
    • Li-Ye Bei
    • Wei Xu

    Original Article 23 November 2023 Pages: 833 - 841

    

16. Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia

    • Hisashi Ishida
    • Yuki Arakawa
    • Toshihiko Imamura

    Original Article 25 November 2023 Pages: 843 - 854

    

17. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial

    • Huixing Zhou
    • Yafei Wang
    • Wenming Chen

    Original Article Open access 19 December 2023 Pages: 855 - 868

    

18. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS

    • Zheng Cao
    • Xiaojun Wang
    • Xiaoli Feng

    Original Article 01 December 2023 Pages: 869 - 883

    

19. Appropriate timing to perform an interim ¹⁸F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma

    • Rang Wang
    • Yue Zhang
    • Minggang Su

    Original Article 30 November 2023 Pages: 885 - 892

    

20. Optimal dosage of rituximab for children with Burkitt lymphoma

    • Shuang Huang
    • Ling Jin
    • Huyong Zheng

    Original Article 13 December 2023 Pages: 893 - 903

    

21. Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management

    • Arif Akyildiz
    • Rashad Ismayilov
    • Ibrahim Barista

    Original Article 07 December 2023 Pages: 905 - 915

    

22. The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping

    • Xiaojin Wu
    • Xiao Ma
    • Depei Wu

    Original Article Open access 16 January 2024 Pages: 917 - 933

    

23. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation

    • Takafumi Tsushima
    • Shin-Ichi Masuda
    • Nobuyuki Aotsuka

    Original Article Open access 29 December 2023 Pages: 935 - 946

    

24. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

    • Francesco Marchesi
    • Irene Terrenato
    • Andrea Mengarelli

    Original Article Open access 08 January 2024 Pages: 947 - 956

25. Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients

    • Kiyan Heybati
    • Domenic Ochal
    • Hemang Yadav

    Original Article 03 January 2024 Pages: 957 - 967

    

26. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy

    • Yifan Zhao
    • Xiaomei Zhang
    • Mingfeng Zhao

    Original Article 12 January 2024 Pages: 969 - 980

    

27. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study

    • Ivo Demel
    • David Skopal
    • Roman Hájek

    Original Article Open access 14 December 2023 Pages: 981 - 992

    

28. VEXAS syndrome: complete molecular remission after hypomethylating therapy

    • Katja Sockel
    • Katharina Götze
    • Christian Thiede

    Case Report Open access 12 January 2024 Pages: 993 - 997

    

29. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review

    • Qiuyan Wang
    • Yajing Zhao
    • Chuanfang Liu

    Case Report 29 January 2024 Pages: 999 - 1005

    

30. Warm autoimmune hemolytic anemia associated with SARS-CoV-2 infection responsive to eculizumab

    • Yuemin Gong
    • Xinyu Zhang
    • Jianyong Li

    Letter to the Editor 27 November 2023 Pages: 1007 - 1009

    

31. Diamond-Blackfan anemia with very late and fatal onset aplasia in a 55-year-old patient with RPL11 mutation

    • Bernhard Strasser
    • Sonja Heibl
    • Alexander Haushofer

    Letter to the Editor 23 November 2023 Pages: 1011 - 1012

32. Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management

    • John Donald Marra
    • Filippo Frioni
    • Patrizia Chiusolo

    Letter to the Editor 29 November 2023 Pages: 1013 - 1014

    

33. Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab

    • Marko Lucijanic
    • Anica Sabljic
    • Rajko Kusec

    Letter to the Editor 25 November 2023 Pages: 1015 - 1016

34. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine

    • Kebing Lv
    • Fancong Kong
    • Fei Li

    Letter to the Editor Open access 29 December 2023 Pages: 1017 - 1019

    

35. Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib

    • Ivan Krečak
    • Eva Čubrić
    • Marko Skelin

    Correspondence 15 December 2023 Pages: 1021 - 1023

    

36. Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with β-thalassemia

    • Simona Leoni
    • Rayan Bou-Fakhredin
    • Irene Motta

    LETTER TO THE EDITOR 03 January 2024 Pages: 1025 - 1026

    

37. Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript

    • Julien Dereme
    • Sophie Voruz
    • Sabine Blum

    Letter to the Editor 09 January 2024 Pages: 1027 - 1029

    

38. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center

    • Alice Kennedy
    • Shyam Patel
    • Jan Cerny

    Letter to the Editor 09 January 2024 Pages: 1031 - 1033